Instil Bio, Inc. (NASDAQ: TIL)

This investigation is for anyone who acquired securities in Instil Bio, Inc. (NASDAQ: TIL) prior to October 31, 2022.

The Law Offices of Howard G. Smith believes that the Company and certain of its executives violated federal law. Specifically, the Law Offices of Howard G. Smith believes that the Company misled investors regarding its financial condition. More specifically, the Law Offices of Howard G. Smith believes that the Company misled investors by telling investors that it had controls in place to be able to safely produce its drug, ITIL-168, but then being unable to safely produce the drug.

On October 31, 2022, before market hours, Instil Bio announced that it was voluntarily pausing enrollment in ongoing clinical trials due to “a recent decrease in the rate of successful manufacturing of ITIL-168, resulting in the inability to dose some patients whose individual product of ITIL-168 was not successfully manufactured.” On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Instil Bio, Inc. (NASDAQ: TIL) prior to October 31, 2022 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.